Baricitinib for Refractory Takayasu Arteritis

Sponsor
Liu Tian
Study ID
NCT06662721
Phase
PHASE2
Status
Completed

Conditions

  • Takayasu Arteritis

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Baricitinib 4 MG — DRUG
    The patients received Baricitinib for 48 weeks. The method is to take Baricitinib 4mg every day for a period of 48 weeks. All the patients will be followed up prospectively for 48 weeks.

Study Details

Takayasu arteritis (TKA) is an autoimmune vasculitis characterized with involvement of aorta and its primary branches. For TKA refractory to TNF-α, Baricitinib, a reversible inhibitor of Janus kinases (JAK) family members JKA1 and JAK2, represents a potential treatment option. This study aims to assess the efficacy and safety of Baricitinib in TKA refractory to TNF-α inhibitors.

Key Dates

Start date
Apr 3, 2023
Status verified
Sep 2024
Primary completion
Dec 23, 2023
Completion
Jun 8, 2024

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treated with baricitinib
    Ten patients with Takayasu arteritis refractory TNF-α inhibirors were treated with baricitinib.

Primary Outcome Measure

Patients achieving complete remission and partial remission [ Time Frame: Week 24 ]

Related Studies